Although there have been no clinical reports suggesting that the exogenous G-CSF treatment have a negative impact on the survival of cancer patients, the impact of G-CSF treatment on the survival or the progression of patients with ovarian cancer has been undetermined. The gene discussed is CSF3; the disease is ovarian carcinoma.